Astellas Pharma Inc
TSE:4503
Astellas Pharma Inc
TSE:4503
Price:
1 530.5
JPY
0.76%
Market Closed
Market Cap:
2.8T
JPY
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Astellas Pharma Inc
1530.5
+11.5 (+0.76%)
| 52 Week Range |
1 446
1 828
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Astellas Pharma Inc
Balance Sheet
Balance Sheet Decomposition
Astellas Pharma Inc
Astellas Pharma Inc
| Current Assets | 1.2T |
| Cash & Short-Term Investments | 329.3B |
| Receivables | 570.9B |
| Other Current Assets | 302.9B |
| Non-Current Assets | 2.3T |
| Long-Term Investments | 123B |
| PP&E | 315.3B |
| Intangibles | 1.7T |
| Other Non-Current Assets | 99.8B |
| Current Liabilities | 1.1T |
| Accounts Payable | 161.2B |
| Other Current Liabilities | 932.2B |
| Non-Current Liabilities | 839B |
| Long-Term Debt | 620.2B |
| Other Non-Current Liabilities | 218.8B |
Balance Sheet
Astellas Pharma Inc
Astellas Pharma Inc
Currency: JPY
| Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
348 343
|
346 879
|
331 801
|
328 669
|
297 477
|
313 126
|
326 128
|
315 986
|
376 840
|
335 687
|
|
| Cash Equivalents |
348 343
|
346 879
|
331 801
|
328 669
|
297 477
|
313 126
|
326 128
|
315 986
|
376 840
|
335 687
|
|
| Short-Term Investments |
48 226
|
13 641
|
9 122
|
3 062
|
13 597
|
11 817
|
0
|
2 281
|
106
|
93
|
|
| Total Receivables |
399 749
|
358 106
|
334 357
|
341 441
|
365 348
|
373 505
|
362 722
|
423 018
|
465 455
|
576 726
|
|
| Accounts Receivables |
332 923
|
327 599
|
309 817
|
319 512
|
342 628
|
347 042
|
343 178
|
382 462
|
427 965
|
534 985
|
|
| Other Receivables |
66 826
|
30 507
|
24 540
|
21 929
|
22 720
|
26 463
|
19 544
|
40 556
|
37 490
|
41 741
|
|
| Inventory |
156 907
|
161 691
|
182 537
|
147 626
|
151 511
|
151 017
|
164 080
|
153 072
|
174 386
|
248 738
|
|
| Other Current Assets |
12 733
|
17 220
|
18 848
|
24 821
|
29 226
|
18 049
|
19 658
|
28 997
|
33 167
|
33 486
|
|
| Total Current Assets |
965 958
|
897 537
|
876 665
|
845 619
|
857 159
|
867 514
|
872 588
|
923 354
|
1 049 954
|
1 194 730
|
|
| PP&E Net |
202 869
|
200 955
|
191 115
|
181 295
|
173 483
|
268 600
|
264 623
|
269 044
|
286 459
|
293 742
|
|
| PP&E Gross |
202 869
|
200 955
|
191 115
|
181 295
|
173 483
|
268 600
|
264 623
|
269 044
|
286 459
|
293 742
|
|
| Accumulated Depreciation |
269 258
|
279 641
|
278 073
|
283 414
|
274 762
|
295 586
|
327 707
|
355 010
|
374 379
|
395 737
|
|
| Intangible Assets |
295 844
|
339 202
|
387 419
|
416 912
|
429 707
|
724 773
|
651 427
|
623 431
|
562 496
|
1 453 824
|
|
| Goodwill |
136 337
|
150 660
|
168 521
|
212 976
|
225 864
|
278 253
|
284 011
|
303 030
|
328 411
|
418 694
|
|
| Note Receivable |
26 511
|
35 631
|
32 684
|
36 027
|
34 912
|
46 570
|
45 188
|
40 666
|
32 793
|
27 762
|
|
| Long-Term Investments |
101 190
|
80 383
|
54 178
|
59 780
|
75 462
|
66 399
|
91 704
|
91 009
|
101 955
|
116 659
|
|
| Other Long-Term Assets |
64 869
|
94 970
|
103 490
|
105 596
|
101 061
|
63 060
|
64 087
|
81 861
|
94 450
|
64 192
|
|
| Other Assets |
136 337
|
150 660
|
168 521
|
212 976
|
225 864
|
278 253
|
284 011
|
303 030
|
328 411
|
418 694
|
|
| Total Assets |
1 793 578
N/A
|
1 799 338
+0%
|
1 814 072
+1%
|
1 858 205
+2%
|
1 897 648
+2%
|
2 315 169
+22%
|
2 273 628
-2%
|
2 332 395
+3%
|
2 456 518
+5%
|
3 569 603
+45%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
226 602
|
181 559
|
182 826
|
140 909
|
185 280
|
171 954
|
124 777
|
130 739
|
140 236
|
185 193
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
326 000
|
120 000
|
140 000
|
75 000
|
420 393
|
|
| Current Portion of Long-Term Debt |
1 339
|
1 505
|
499
|
444
|
430
|
18 105
|
16 101
|
17 730
|
13 546
|
66 829
|
|
| Other Current Liabilities |
192 949
|
230 295
|
216 531
|
280 267
|
311 955
|
282 649
|
331 494
|
398 942
|
497 252
|
613 310
|
|
| Total Current Liabilities |
420 890
|
413 359
|
399 856
|
421 620
|
497 665
|
798 708
|
592 372
|
687 411
|
726 034
|
1 285 725
|
|
| Long-Term Debt |
626
|
722
|
28 389
|
49 422
|
52 882
|
129 272
|
142 163
|
55 014
|
111 461
|
518 494
|
|
| Deferred Income Tax |
2
|
0
|
18 514
|
26 426
|
5 175
|
24 670
|
18 161
|
5 823
|
6 048
|
51 346
|
|
| Other Liabilities |
54 108
|
126 048
|
95 503
|
92 448
|
83 530
|
73 351
|
134 817
|
123 839
|
105 021
|
118 050
|
|
| Total Liabilities |
475 662
N/A
|
540 129
+14%
|
542 262
+0%
|
589 916
+9%
|
639 252
+8%
|
1 026 001
+61%
|
887 513
-13%
|
872 087
-2%
|
948 564
+9%
|
1 973 615
+108%
|
|
| Equity | |||||||||||
| Common Stock |
103 001
|
103 001
|
103 001
|
103 001
|
103 001
|
103 001
|
103 001
|
103 001
|
103 001
|
103 001
|
|
| Retained Earnings |
905 083
|
973 054
|
1 015 707
|
977 553
|
993 084
|
906 750
|
954 034
|
944 891
|
908 694
|
809 776
|
|
| Additional Paid In Capital |
176 822
|
176 903
|
177 091
|
177 219
|
177 301
|
177 506
|
177 830
|
179 467
|
181 280
|
184 070
|
|
| Unrealized Security Profit/Loss |
28 588
|
29 103
|
14 629
|
18 289
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Treasury Stock |
86 997
|
157 111
|
138 207
|
135 951
|
164 629
|
7 178
|
15 377
|
13 934
|
25 123
|
33 783
|
|
| Other Equity |
179 546
|
134 259
|
99 589
|
128 178
|
149 639
|
109 089
|
166 627
|
246 883
|
340 102
|
532 924
|
|
| Total Equity |
1 317 916
N/A
|
1 259 209
-4%
|
1 271 810
+1%
|
1 268 289
0%
|
1 258 396
-1%
|
1 289 168
+2%
|
1 386 115
+8%
|
1 460 308
+5%
|
1 507 954
+3%
|
1 595 988
+6%
|
|
| Total Liabilities & Equity |
1 793 578
N/A
|
1 799 338
+0%
|
1 814 072
+1%
|
1 858 205
+2%
|
1 897 648
+2%
|
2 315 169
+22%
|
2 273 628
-2%
|
2 332 395
+3%
|
2 456 518
+5%
|
3 569 603
+45%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
2 193
|
2 125
|
2 065
|
1 976
|
1 886
|
1 858
|
1 853
|
1 827
|
1 797
|
1 793
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
